Wedbush raised the firm’s price target on Neurocrine (NBIX) to $141 from $137 and keeps an Outperform rating on the shares. While Neurocrine reported another Ingrezza beat, Crenessity stole the show with $53M well ahead of consensus $16M, WS $18M. With patient demand continuing to increase, Wedbush is pulling forward its Crenessity launch trajectory and now model FY25-FY26 revenue of $233M and $502M, respectively.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Buy Rating for Neurocrine’s Crenessity Driven by Strong Sales and Transformative Impact on CAH Treatment
- Neurocrine price target raised to $145 from $140 at JPMorgan
- Neurocrine’s Strong Financial Performance and Growth Prospects Drive Buy Rating
- Neurocrine’s Promising Growth Trajectory: Buy Rating Affirmed Amid Strong Commercial Execution and Growth Opportunities
- Positive Outlook for Neurocrine: Strong Performance and Growth Potential Drive Buy Rating